<div class="" data-article-body="true">A long-awaited change in drug policy could bring scientists one step closer to understanding the harms and benefits of marijuana, the most commonly used federally illegal substance.On Thursday, <a href="https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/" rel="nofollow noopener" target="_blank" data-ylk="slk:President Donald Trump signed an executive order;elm:context_link;itc:0;sec:content-canvas" class="link ">President Donald Trump signed an executive order </a>that moved to <a href="https://www.nbcnews.com/politics/trump-administration/trump-signs-executive-order-fast-tracking-reclassification-marijuana-rcna249741" rel="nofollow noopener" target="_blank" data-ylk="slk:reclassify cannabis;elm:context_link;itc:0;sec:content-canvas" class="link ">reclassify cannabis</a> from a Schedule I to a Schedule III substance, following through on a regulatory shift first pushed during the Biden administration.“Decades of federal drug control policy have neglected marijuana’s medical uses,” the order says. “That oversight has limited the ability of scientists and manufacturers to complete the necessary research on safety and efficacy to inform doctors and patients.”While the reclassification is intended to bolster medical marijuana research and won’t <a href="https://www.nbcnews.com/legal-pot" rel="nofollow noopener" target="_blank" data-ylk="slk:legalize cannabis;elm:context_link;itc:0;sec:content-canvas" class="link ">legalize cannabis</a> at the federal level, the move comes at a time when use in the United States is at a high. <a href="https://news.gallup.com/poll/284135/percentage-americans-smoke-marijuana.aspx" rel="nofollow noopener" target="_blank" data-ylk="slk:Gallup data;elm:context_link;itc:0;sec:content-canvas" class="link ">Gallup data</a> from 2023 and 2024 estimates that 15% of adults smoke marijuana, up from 7% in 2013.The poll, which didn’t differentiate between medical and recreational consumption, showed the highest use (19%) among young adults 18 to 34, a group for whom studies have found cannabis to have damaging psychiatric effects. For example, a study published Tuesday in the journal <a href="http://dx.doi.org/10.1542/peds.2024-070509" rel="nofollow noopener" target="_blank" data-ylk="slk:Pediatrics;elm:context_link;itc:0;sec:content-canvas" class="link ">Pediatrics</a> found that using marijuana as little as once or twice a month was linked to emotional distress and worse school performance among teens.Medical marijuana is typically prescribed to ease chronic pain; control nausea and vomiting, often in people receiving chemotherapy for cancer; and bring about an appetite in people with certain medical conditions. It’s unclear whether rescheduling cannabis will affect funding for recreational marijuana research.Scientists like Ziva Cooper are hopeful the reclassification could revolutionize public health through more comprehensive marijuana research.“It is extremely difficult to study cannabis, aka marijuana, for both the potential adverse effects as well as therapeutic effects,” said Cooper, director of the Center for Cannabis and Cannabinoids at the University of California, Los Angeles. “The industry is developing at a very fast pace, and so consumer behavior is developing along with that industry.“It’s very hard for us, as scientists, as people who are interested in public health, to be able to keep up with the changes, in part because the research is difficult.”Schedule I is the strictest of the five controlled substance categories recognized by the <a href="https://www.dea.gov/drug-information/drug-scheduling" rel="nofollow noopener" target="_blank" data-ylk="slk:Drug Enforcement Administration;elm:context_link;itc:0;sec:content-canvas" class="link ">Drug Enforcement Administration</a>, reserved for drugs “with no currently accepted medical use and a high potential for abuse,” including ecstasy, heroin, LSD and peyote. Schedule III drugs, which include <a href="https://www.nbcnews.com/health/health-news/matthew-perry-ketamine-drug-what-used-for-rcna166904" rel="nofollow noopener" target="_blank" data-ylk="slk:ketamine;elm:context_link;itc:0;sec:content-canvas" class="link ">ketamine</a>, <a href="https://www.nbcnews.com/health/mens-health/fda-panel-testosterone-replacement-therapy-rcna248053" rel="nofollow noopener" target="_blank" data-ylk="slk:testosterone;elm:context_link;itc:0;sec:content-canvas" class="link ">testosterone</a> and <a href="https://www.nbcnews.com/tech/internet/natty-not-steroid-discussions-rcna42034" rel="nofollow noopener" target="_blank" data-ylk="slk:anabolic steroids;elm:context_link;itc:0;sec:content-canvas" class="link ">anabolic steroids</a>, have “a moderate to low potential for physical and psychological dependence,” according to the agency.Despite working in a cannabis-friendly state, Cooper said she faces the same research hurdles as her peers in states such as Idaho, where no marijuana use is permitted whatsoever.“Researchers cannot test what is readily available to the market, just basic questions about what is in those products that are available in the dispensary I can see outside of my laboratory window, for example,” Cooper said. “It also means that there are certain restrictions with respect to where we can get our cannabis that we do research on.”<h2 class="mb-4 text-xl font-bold md:text-2xl">Harms and benefits of marijuana need further study</h2>Last year, the <a href="https://report.nih.gov/funding/categorical-spending#/" rel="nofollow noopener" target="_blank" data-ylk="slk:National Institutes of Health;elm:context_link;itc:0;sec:content-canvas" class="link ">National Institutes of Health</a> awarded $75 million to therapeutic cannabinoid research, up from $70 million in 2023. Additionally, $217 million went to cannabinoids, or cannabis compounds, and $53 million went to <a href="https://www.nbcnews.com/health/health-news/cbd-liver-damage-study-potential-problems-rcna217186" rel="nofollow noopener" target="_blank" data-ylk="slk:cannabidiol, or CBD;elm:context_link;itc:0;sec:content-canvas" class="link ">cannabidiol, or CBD</a>, a nonpsychoactive cannabinoid.However, administrative red tape means cannabis studies are often observational, compared with the rigorous clinical trials required of pharmaceutical research, said Dr. Brooke Worster, medical director of the M.S. in medical cannabis science and business program at Thomas Jefferson University in Philadelphia. Their findings have been mixed.For example, a 2024 study published in the journal <a href="https://www.benthamscience.com/article/138726" rel="nofollow noopener" target="_blank" data-ylk="slk:Current Alzheimer Research;elm:context_link;itc:0;sec:content-canvas" class="link ">Current Alzheimer Research</a> found that recreational cannabis use among adults 45 and older was associated with a 96% lower risk of subjective cognitive decline, compared with nonusers. Yet a 2025 study published in <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829657" rel="nofollow noopener" target="_blank" data-ylk="slk:JAMA Network Open;elm:context_link;itc:0;sec:content-canvas" class="link ">JAMA Network Open</a> found that among adults 22 to 36, heavy cannabis users showed impaired <a href="https://www.nbcnews.com/health/aging/brain-game-boosts-chemical-memory-dementia-research-rcna237832" rel="nofollow noopener" target="_blank" data-ylk="slk:working memory;elm:context_link;itc:0;sec:content-canvas" class="link ">working memory</a>.Research published this year in the journal Biomedicines suggested cannabinoids are a “promising” alternative to opioids for chronic pain management but cited an urgent need for large-scale, randomized controlled trials. Meanwhile, a study published last year in <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820100" rel="nofollow noopener" target="_blank" data-ylk="slk:JAMA Network Open;elm:context_link;itc:0;sec:content-canvas" class="link ">JAMA Network Open</a> found that older, Medicare-insured adults showed increased rates of health care visits involving cannabis-related disorders from 2017 through 2022.The reclassification will allow researchers to dispense and study specific formulations of marijuana, Worster said. Now, even in states with medical marijuana programs, the quality and potency of cannabis products can vary greatly between dispensaries.“We can actively track immediate symptoms or blood levels of things, longer-term effects,” she said. “All the things you’d want to do when you’re studying a medication, all the things that the federal government otherwise requires us to do to study a medication.”While marijuana may have some medical benefits for some people, Jonathan Caulkins, the H. Guyford Stever university professor of operations research and public policy at Carnegie Mellon University in Pittsburgh, denied that administrative roadblocks have prevented cannabis from curing ailments such as cancer or <a href="https://www.nbcnews.com/health/health-news/people-younger-brains-muscle-mass-less-visceral-fat-rcna245185" rel="nofollow noopener" target="_blank" data-ylk="slk:Alzheimer’s disease;elm:context_link;itc:0;sec:content-canvas" class="link ">Alzheimer’s disease</a>.“They do not restrict research in Canada or France or Israel,” Caulkins said. “I don’t think that we should imagine that the only reason cannabis hasn’t become the wonder drug is because of anything about U.S. law, because we’re not the only country in the world that has a pharmaceutical industry and a research base.”Still, the change brings new responsibility to the medical community, Worster said, as smoked and <a href="https://www.nbcnews.com/health/health-news/cdc-fda-find-youth-vaping-drops-lowest-level-decade-rcna169699" rel="nofollow noopener" target="_blank" data-ylk="slk:inhaled products;elm:context_link;itc:0;sec:content-canvas" class="link ">inhaled products</a> of any concentration or formulation aren’t safe for everyone.“What still needs to be figured out is, how do we get the right patient the right medication and the right guidance?” she said. “The products out there are, a lot of times, not regulated. There are real risks with mental health, with youth who use it too regularly, certainly some <a href="https://www.nbcnews.com/health/heart-health/uterine-fibroids-heart-disease-risk-women-study-rcna248368" rel="nofollow noopener" target="_blank" data-ylk="slk:cardiovascular effects;elm:context_link;itc:0;sec:content-canvas" class="link ">cardiovascular effects</a> that we need to pay more attention to.”<h2 class="mb-4 text-xl font-bold md:text-2xl">Cannabis policy to be revised after 55 years</h2>The <a href="https://www.nbcnews.com/politics/donald-trump/trump-expected-order-reclassify-cannabis-open-medical-pot-rcna249550" rel="nofollow noopener" target="_blank" data-ylk="slk:regulatory hurdles;elm:context_link;itc:0;sec:content-canvas" class="link ">regulatory hurdles</a> researchers face date back more than half a century. During the Nixon administration, the Controlled Substances Act of 1970 established cannabis as a Schedule I drug.Nearly 60 years later, much of marijuana’s medical potential, or lack thereof, remains unknown. In the eyes of the law, Worster said, “it is simply a drug of abuse.”Susan Ferguson, director of the Addictions, Drug and Alcohol Institute at the University of Washington School of Medicine, anticipates scientists will soon have an easier time acquiring cannabis research licenses. Currently, she said, researchers may obtain a broad license to study any Schedule II through V drug. Those who wish to study a Schedule I drug must get a separate license for each substance.“It involves extensive writing of protocols,” she said. “It involves DEA agents coming out and inspecting the lab and talking to me about the research and the plans for the experiments. It gets very, very complicated.”Rescheduling marijuana, Ferguson said, would “open the floodgates” for clinical research. For starters, people may be more inclined to enroll in studies of Schedule III rather than Schedule I drugs.Ferguson likened cannabis to <a href="https://www.nbcnews.com/health/cancer/cancer-deaths-linked-alcohol-rise-us-rcna208319" rel="nofollow noopener" target="_blank" data-ylk="slk:alcohol;elm:context_link;itc:0;sec:content-canvas" class="link ">alcohol</a> and <a href="https://www.nbcnews.com/health/kids-health/tobacco-use-teens-soars-erasing-past-progress-cdc-says-n970321" rel="nofollow noopener" target="_blank" data-ylk="slk:tobacco;elm:context_link;itc:0;sec:content-canvas" class="link ">tobacco</a> — products that are commonplace but not harmless. Medical research is the reason their harms are well known.“We haven’t done that research on cannabis,” Ferguson said. “It’ll be able to ultimately tell people what are the risks, what are the benefits, and just give people more information.”This article was originally published on <a href="https://www.nbcnews.com/health/health-news/medical-marijuana-research-open-floodgates-cannabis-reclassification-rcna249811" rel="nofollow noopener" target="_blank" data-ylk="slk:NBCNews.com;elm:context_link;itc:0;sec:content-canvas" class="link ">NBCNews.com</a></div>

A long-awaited change in drug policy by President Donald Trump could bring scientists one step closer to understanding the harms and benefits of marijuana.

Cannabis reclassification could 'open the floodgates' for research, scientists say

Notably, Germany opposed various sanctions proposals in the EU. It is one of the few countries Israel can count on to at least abstain from one-sided UN General Assembly resolutions.

Merz visit highlights new strategic, and strained, Germany-Israel bond

Spotify on Wednesday unveiled Wrapped, its annual year-end campaign that ranks which songs, albums and artists topped the streaming platform's charts for 2025.

Spotify Wrapped and Apple Music Replay are here: Top songs, albums and artists of 2025

Australia is a place where there is different scenes, remarkable untamed life, and rich social legacy. This casting a ballot article features six of the top high priority attractions in Australia, each offering a remarkable


Must-See Attractions in Australia


History class frequently gives us charming realities, yet a large number of them are widely known. Digging into less popular verifiable goodies


Reveal Less popular Authentic Realities You Didn't Learn in School


BERLIN () -German pharma company Bayer reported positive study ​results for its anticoagulant asundexian on Sunday,‌ two years after a research setback for the ‌promising blood thinner candidate. In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared ⁠with a placebo,‌ Bayer said.

Bayer reports positive results for blood thinner after 2023 setback

ATLANTA - Federal vaccine advisers selected by Health Secretary Robert F. Kennedy Jr. delayed until Friday a vote to lift a long-standing recommendation for all newborns to get the hepatitis B vaccine in what would be the most sweeping revision to the childhood vaccine schedule under Kennedy. The advisers heard presentations in the morning - including from two prominent vaccine critics recently hired by the Centers for Disease Control and Prevention - casting doubt on the safety and necessity of

CDC vaccine panel delays vote to stop recommending hepatitis B shot at birth

Drone strikes on a town in South Kordofan on Thursday are said to have killed at least 50 people.

Deadly attack on kindergarten reported in Sudan

Perfect gems pieces are immortal fortunes that dazzle with their brightness, craftsmanship, and history. From astonishing precious stones to dynamic hued


The Magnificence of Extraordinariness: Presenting Valuable Adornments and Gemstones


Keeping a solid and dynamic way of life is fundamental for in general prosperity and essentialness. Integrating solid propensities into your everyday daily schedule


7 Moves toward a Sound and Dynamic Way of life


A coalition led by Iraqi Prime Minister Mohammed Shia al-Sudani won Iraq's parliamentary election, according to local media on Wednesday. After counting more than 99% of the votes, al-Sudani's Reconstruction and Development Coalition secured more than 1.

Coalition led by Iraqi PM al-Sudani wins parliamentary elections

Picking the right climbing boots is fundamental for an agreeable and safe climbing experience. The best climbing boots offer help,


Vote in favor of Your #1 Climbing boots Now


America's relationship with inexpensive food is notable, and throughout the long term, certain brands have arisen as top choices across the


Tasting America: An Excursion Through Darling Cheap Food Brands


Luigi Mangione’s lawyers contend that Attorney General Pam Bondi’s decision to seek the death penalty against him in the killing of UnitedHealthcare CEO Brian Thompson was tainted by her prior work as a lobbyist at a firm that represented the insurer’s parent company.  Bondi was a partner at Ballard Partners before leading the Justice Department’s charge to turn Mangione’s federal prosecution into a capital case, creating a “profound conflict of interest” that violated his due process rights, hi

Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest

Picking the right bed is fundamental for a decent night's rest and generally prosperity. In 2024, the market offers a
